首页 | 本学科首页   官方微博 | 高级检索  
     

Toll样受体7及9在慢性粒细胞白血病患者浆细胞样树突状细胞内的表达
引用本文:段丽芳,张连生,岳玲玲,柴晔,曾鹏云,吴重阳,李莉娟. Toll样受体7及9在慢性粒细胞白血病患者浆细胞样树突状细胞内的表达[J]. 中国肿瘤生物治疗杂志, 2012, 19(3): 257-260
作者姓名:段丽芳  张连生  岳玲玲  柴晔  曾鹏云  吴重阳  李莉娟
作者单位:兰州大学第二医院血液科,甘肃兰州,730030
基金项目:甘肃省科技支撑计划资助项目(No. 0804NKCA115)
摘    要:目的:研究Toll样受体7(Toll-like receptor 7,TLR7)mRNA及TLR9 mRNA在慢性粒细胞白血病(chronic myeloid leukemia,CML)患者外周血浆细胞样树突状细胞(plasmacytoid dendritic cell,pDC)内的表达及pDC分泌干扰素-α(interferon-α,IFN-α)的能力。方法:收集兰州大学第二医院血液科2010年11月至2011年7月间收治的30例CML患者(初诊未治组15例,缓解组15例)和体检中心的15例健康对照者,运用免疫磁珠法分选外周血pDC,利用real time-PCR检测pDC内TLR7及TLR9 mRNA表达水平。CpG ODN 2216刺激pDC 24 h后,ELISA检测上清液中IFN-α水平。结果:初诊组CML患者外周血pDC内TLR7 mRNA表达水平显著低于缓解组[(0.34±0.11)vs(0.93±0.21),P<0.05],初诊CML患者TLR9 mRNA表达水平显著低于缓解组[(0.44±0.15)vs(0.94±0.18),P<0.05]。CpG ODN 2216刺激后,初诊组pDC产生的IFN-α明显低于缓解组及健康对照组[(408.61±77.11)vs(611.39±84.86)、(651.67±93.39)ng/L,P<0.05]。结论:CML患者pDC内TLR7和TLR9 mRNA明显降低可能是pDC功能缺陷的主要原因,提示TLR7和TLR9可能参与CML的发病。

关 键 词:慢性粒细胞白血病  浆细胞样树突状细胞  Toll样受体7  Toll样受体9
收稿时间:2012-02-01
修稿时间:2012-04-25

Expression of Toll-like receptor 7 and 9 in peripheral blood plasmacytoid dendritic cells of patients with chronic myeloid leukemia
DUAN Li-fang,ZHANG Lian-sheng,YUE Ling-ling,CHAI Ye,ZENG Peng-yun,WU Chong-yang and LI Li-juan. Expression of Toll-like receptor 7 and 9 in peripheral blood plasmacytoid dendritic cells of patients with chronic myeloid leukemia[J]. Chinses Journal of Cancer Biotherapy, 2012, 19(3): 257-260
Authors:DUAN Li-fang  ZHANG Lian-sheng  YUE Ling-ling  CHAI Ye  ZENG Peng-yun  WU Chong-yang  LI Li-juan
Affiliation:Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China;Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China;Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China;Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China;Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China;Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China;Department of Hematology, Second Affiliated Hospital of Lanzhou University, Lanzhou 730030, Gansu, China
Abstract:Objective: To investigate the expression of Toll-like receptor 7(TLR7) mRNA and TLR9 mRNA in the peripheral blood plasmacytoid dendritic cells(pDCs) of patients with chronic myeloid leukemia(CML),and the interferonα(IFN-α) secretion by pDCs.Methods: pDCs were sorted by immune magnetic beads of the patients with CML(n = 30,including 15 CML untreated and 15 CML remission) from the Department of Hematology of Second Affiliated Hospital of Lanzhou University from November 2010 to July 2011 and healthy controls(n = 15) from Physical Examination Center.The mRNA expressions of TLR7 and TLR9 in pDCs were measured with real time-PCR;pDCs were stimulated by CpG ODN 2216 for 24 h,and IFN-α in the supernatant was measured using ELISA.Results: The mRNA expression of TLR7 was significantly reduced in the untreated CML group(0.34 ± 0.11) than that in the remission CML group(0.93 ± 0.21,P < 0.05) and the healthy control group(P < 0.05);The mRNA expression of TLR9 was significantly reduced in the untreated CML group(0.44 ± 0.15) than that in the remission group(0.94 ± 0.18,P < 0.05) and the healthy control group(P < 0.05);IFN-α production of pDCs was significantly reduced in the untreated CML group than that in the remission group and the healthy control group([408.61 ± 77.11]vs [611.39 ± 84.86],[651.67 ± 93.39]ng/L,P < 0.05).Conclusion: The mRNA expressions of TLR7 and TLR9 are significantly reduced in CML patients,which may be the main reason of function defects of pDCs,indicating that TLR7 and TLR9 may be involved in the pathogenesis of CML.
Keywords:chronic myeloid leukemia   plasmacytoid dendritic cell   toll-like receptor 7   toll-like receptor 9
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国肿瘤生物治疗杂志》浏览原始摘要信息
点击此处可从《中国肿瘤生物治疗杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号